Following the release of the Q1 2026 report, Physitrack's CEO, Henrik Molin, joins us to discuss the group's transition from structural cleanup to commercial execution. While the "SaaS-only" reset has successfully fortified the bottom line with a robust 34% Adjusted EBITDA margin, headline growth has remained modest. We dive into the strategic logic behind the imminent North American launch of the Remote Therapeutic Monitoring (RTM) platform and how it repositions the software from a cost to a revenue-enabling tool for clinics. With the operational leverage gained from the restructuring and the new New York hub, we explore why 2026 is set to be the year Physitrack pivots toward accelerated growth.
LÄS MER
